Clinical Trial Update: A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957) [Phase 2]

View source ↗

Summary

Phase 2 bridging trial evaluating Sugammadex (Org 25969) at 1-2 post-tetanic count in Japanese participants; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anesthesia General

Drugs mentioned

• Sugammadex (sugammadex)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Anesthesia, General | Phase 2 | Status: COMPLETED | Results posted: 2019-02-18